ArticleGenome research2025
Interpretable phenotype decoding from multicondition sequencing data with ALPINE.
Article in Genome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As sequencing techniques advance in precision, affordability, and diversity, an abundance of heterogeneous sequencing data has become available, encompassing a wide range of phenotypic features and biological perturbations. Unfortunately, increased resolution comes with the cost of increased complexity of the biological search space, even at the individual study level, as perturbations are now often examined across many dimensions simultaneously, including different donor phenotypes, anatomical regions and cell types, and time points. Furthermore, broad integration across studies promises a unique opportunity to explore the molecular underpinnings of distinct healthy and disease states, larger than the original scope of the individual study. To fully realize the promise of both individual higher resolution studies and large cross-study integrations, we need a robust methodology that can disentangle the influence of technical and nonrelevant phenotypic factors, isolating relevant condition-specific signals from shared biological information while also providing interpretable insights into the genetic effects of these conditions. Current methods typically excel in only one of these areas. To address this gap, we have developed ALPINE, a supervised nonnegative matrix factorization (NMF) framework that effectively separates both technical and nontechnical factors while simultaneously offering direct interpretability of condition-associated genes. Through simulations across four different scenarios, we demonstrate that ALPINE outperforms existing methods in both isolating the effect of different phenotypic conditions and prioritizing condition-associated genes. Furthermore, ALPINE has favorable performance in batch effect removal compared with state-of-the-art integration methods. When applied to real-world case studies, we showcase how ALPINE can be used to extract insights into the biological mechanisms that underlie differences between phenotypic conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.